Skip to main content
. 2018 Jun 6;5(3):290–299. doi: 10.1016/j.gendis.2018.05.004

Figure 5.

Figure 5

Effect of rosiglitazone (Rosi) or CMHX008 (CMHX) on the differentiation of mesenchymal stem cells (MSCs) into osteoblasts. (A) Protein levels of the osteogenic marker gene OCN and Runx2 in MSCs after treatment with vehicle (Veh), rosiglitazone (Rosi) or CMHX008 (CMHX) for 7 days. (B) Representative ALP staining of osteoblasts after treatment for 14 days. Scale bar = 50 μm. (C) Quantitative ALP concentration after treatment for 14 days. (D) Expression of osteogenic marker genes by RT-PCR after treatment for 14 days. (E) Alizarin red staining of mineralized nodules after treatment for 21 days. *P < 0.05, **P < 0.01 versus Veh, #P < 0.05, ##P < 0.01 versus Rosi.